Business / Finance

RSS

Medtronic enters definitive agreement to acquire PEAK Surgical

Medtronic, Inc. today announced that it has entered into a definitive agreement to acquire PEAK Surgical, Inc., a recognized leader in the emerging field of advanced energy surgical incision technology to broaden Medtronic Surgical Technologies' portfolio of innovative surgical products to meet customer and patient needs worldwide.

From Medtronic 8 Jul 2011

Managed care enters the exam room as insurers buy doctor groups

Kaiser Health News staff writer Christopher Weaver, working in collaboration with The Washington Post, reports: "Even if UnitedHealth Group isn't your insurance company, there's a good chance it touches you in some way.

6 Jul 2011

Erratic investment responses can make a smart portfolio richer

Playing the stock market can be a risky game. And when the market behaves unpredictably, public fear can lead to erratic investment responses and market chaos.

1 Jul 2011

Premature ejaculation treatment market to reach over $1.3 billion by 2017

In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com.

30 Jun 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

AEGEA completes $13.3M private equity financing

AEGEA Medical Inc., developer of a novel, minimally invasive treatment for abnormal uterine bleeding, reported today that it has completed a $13.3 million private equity financing led by Covidien Ventures.

30 Jun 2011

Golden Meditech total turnover increases 15% to HK$328,066,000 for year ended 31 March, 2011

Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, is pleased to announce the Group's annual results for the year ended 31 March, 2011.

30 Jun 2011

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors.

30 Jun 2011

China Health first quarter gross revenues increase 52% to $6.759 million

China Health Labs & Diagnostics Ltd. is pleased to announce the financial results for the first quarter ended March 31, 2011.

29 Jun 2011

Exciton enters distribution agreement with Marathon Medical

Exciton Technologies Inc. today announced the Company has signed a distribution agreement with Marathon Medical, adding them to the existing Federal Supply Schedule (FSS) contract, administered by the Department of Veterans Affairs on behalf of the U.S. General Services Administration (GSA), effective July 1st.

29 Jun 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States.

29 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

RxMD and GlycoRegImmune enter drug development collaboration

RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that they acquired marketing and distribution rights to several unique branded products for the treatment of pain from Atley Pharmaceuticals. Some products are approved and some are pending approval with the Food and Drug Administration (FDA).

29 Jun 2011

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).

29 Jun 2011

Aetna acquires Prodigy Health Group

Aetna today announced that it has completed its acquisition of Prodigy Health Group, the nation's largest independent third party administrator (TPA) of self-funded health care plans.

29 Jun 2011